Shimizu T, Tanaka Y, Takeshita N, Matsuda T
Department of Radiation Oncology, Tokyo Metropolitan Komagome Hospital.
Nihon Igaku Hoshasen Gakkai Zasshi. 1992 Jul 25;52(7):993-1000.
During the period from 1975 to 1989, 84 patients with carcinoma of the prostate were treated with conformation radiotherapy at Tokyo Metropolitan Komagome Hospital. The radiation field encompassed only the area of the prostate gland; it did not include the pelvic lymph nodes. The clinical stage of the 84 tumors was 22 in Stage A, 31 in Stage B, 15 in Stage C and 16 in Stage D. The average age of patients was 73.4 years, with range of 54 to 88 years. The average dose to the tumor was 65.7 Gy, with range of 60 Gy to 70 Gy. Hormone therapy was applied to 42 cases. The 5- and 10-year cumulative survival rates were 90.7% and 70.5% for Stage A, 41.7% and 26.7% for Stage B, 48.9% and 48.9% for Stage C, and 32.6% and 0% for Stage D, respectively. The 5-year cause-specific cumulative survival rates were 100% for Stage A, 92.3% for Stage B, 65.0% for Stage C and 40.3% for Stage D, respectively. Patients with poorly differentiated adenocarcinomas or undifferentiated carcinomas showed poorer survival than those with well-differentiated carcinoma. Only 7 cases suffered in-field recurrence, and 2 cases suffered recurrence at pelvic lymph nodes. Acute reactions were noted in 13 cases. Late complications following treatment were acceptable. Mild to moderate complications were recognized in 2 cases, but neither patient required surgery. In conclusion, our data suggest the advantage of the conformation technique applied to radiation therapy for carcinoma of the prostate.
1975年至1989年期间,东京都驹込医院对84例前列腺癌患者进行了适形放疗。放射野仅包括前列腺区域,未包括盆腔淋巴结。84例肿瘤的临床分期为:A期22例,B期31例,C期15例,D期16例。患者的平均年龄为73.4岁,年龄范围为54岁至88岁。肿瘤的平均剂量为65.7 Gy,剂量范围为60 Gy至70 Gy。42例患者接受了激素治疗。A期、B期、C期和D期的5年和10年累积生存率分别为90.7%和70.5%、41.7%和26.7%、48.9%和48.9%、32.6%和0%。A期、B期、C期和D期的5年病因特异性累积生存率分别为100%、92.3%、65.0%和40.3%。低分化腺癌或未分化癌患者的生存率低于高分化癌患者。仅7例出现野内复发,2例出现盆腔淋巴结复发。13例出现急性反应。治疗后的晚期并发症可以接受。2例出现轻度至中度并发症,但均无需手术。总之,我们的数据表明适形技术应用于前列腺癌放射治疗的优势。